Regenerex Pharma (RGPX) Total Current Liabilities (2010 - 2025)

Regenerex Pharma (RGPX) has 14 years of Total Current Liabilities data on file, last reported at $4.9 million in Q3 2025.

• Total Current Liabilities for Q3 2025 came in at $4.9 million, up 1.51% year-over-year; the trailing twelve-month figure through Sep 2025 was $4.9 million (up 1.51% YoY), and the FY2025 annual result was $4.9 million, up 28.11% from the prior year.
• Total Current Liabilities grew to $4.9 million in Q3 2025 per RGPX's latest filing, from $4.9 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $5.2 million in Q4 2024 and troughed at $598829.0 in Q4 2021.
• A 5-year average of $2.5 million and a median of $874874.0 in 2022 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2021 and 2024: Total Current Liabilities dropped 12.53% in 2021, then jumped 450.5% in 2024.
• A 5-year view of Total Current Liabilities shows it stood at $598829.0 in 2021, then soared by 46.1% to $874874.0 in 2022, then soared by 306.88% to $3.6 million in 2023, then soared by 44.96% to $5.2 million in 2024, then declined by 4.58% to $4.9 million in 2025.
• Business Quant data shows RGPX's Total Current Liabilities at $4.9 million in Q3 2025, $4.9 million in Q2 2025, and $4.9 million in Q1 2025.